Pay in 4 interest-free payments of $6.22 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Ozempic approved to reduce cardiovascular risk Ozempic (semaglutide 0.5 mg, 1 mg, and 2 mg) previously received FDA approval for cardiovascular health in people with type 2 diabetes after combined results from the SUSTAIN-6 and PIONEER-6 trials showed a 24% reduction in major adverse cardiac events (MACE) such as heart attack, stroke, and other cardiovascular-related deaths
Always choose FDA-approved, brand-verified, internationally certified products
Full details of the intervention, in accordance with the Consensus on Exercise Reporting Template (CERT), are provided in the supplementary appendix, methods, section D of the primary trial report 11
de Oliveira Almeida G, Nienktter TF, Balieiro CCA, Pasqualotto E, Cintra JB, Carvalho HCP et al
